Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 47 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
VS BioClinical from Saint-Nicolas, company number BE0757634336, closed financial year 2025 with a result of € 178,073 after tax. For that financial year VS BioClinical recorded a gross margin of € 237,696 and equity of € 463,776. Compared with financial year 2024, the result moved from € 190,469 to € 178,073. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 8, 2026.
€ 463,776
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 178,073
▼ 7% vs 2024
Profit after tax over the fiscal year.
€ 79,111
▼ 56% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 178,073 paid out
100 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 3,014
▼ 74% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1,173
▼ 86% vs 2024
Loans from banks and other lenders, long and short.
€ 213
▼ 94% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 24,000
▼ 7% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 248,513 | € 257,953 | € 259,146 | € 237,696 | ▼ 8% |
| Profit after taxes | € 167,563 | € 172,266 | € 190,469 | € 178,073 | ▼ 7% |
| Equity | € 291,511 | € 463,776 | € 463,776 | € 463,776 | |
| Total debts | € 46,038 | € 41,184 | € 228,357 | € 180,606 | ▼ 21% |
| Cash | € 260,875 | € 224,854 | € 181,653 | € 79,111 | ▼ 56% |
| Retained profit | € 289,511 | € 461,776 | € 461,776 | € 461,776 | |
| Dividend | € 0 | € 0 | € 190,469 | € 178,073 | ▼ 7% |
| Bank debt | € 21,945 | € 15,094 | € 8,170 | € 1,173 | ▼ 86% |
| Balance sheet total | € 337,549 | € 504,960 | € 692,134 | € 644,383 | ▼ 7% |
Key figures of VS BioClinical, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to VS BioClinical?
What happened at VS BioClinical in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 178,073 (▼ 7% vs 2024). Source: NBB ↗
- New establishment in Saint-Nicolas. KBO
- Violeta STOJKOVIC became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 167,563 profit in 2022 to € 178,073 profit in 2025.
Paid € 268,604 in corporate taxes since 2022.
Best year ever: 2024, with € 190,469 profit.
Paid out € 368,542 in dividends to the owners in total.
Management
Behind VS BioClinical is Violeta STOJKOVIC.
Directors
According to the 2025 annual accounts
Violeta STOJKOVIC
Director
since 2020
Establishments
Establishment units
Physical locations of this company
Rue Voie des Vaux 34 box 11
4420 Saint-Nicolas
Rue Voie des Vaux 34
4420 Saint-Nicolas
Active since 29 October 2020
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0757.634.336
- VAT number
- BE 0757.634.336
- Registered office
- Rue Voie des Vaux 34 bus 11, 4420 Saint-Nicolas
- Names & denominations
- VS BioClinical
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 October 2020
- Peppol
- Active · Active since 10 Nov 2025